Press Releases Cidara Therapeutics, Inc.

Equities

CDTX

US1717572069

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
12.02 ^USD	+0.84%		+6.75%	-24.31%

May. 15	Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $8.5M	MT
Apr. 25	Top Premarket Gainers	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cidara Therapeutics: Q1 Earnings Snapshot	May. 15	AQ
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	May. 15	AQ
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules	May. 15	AQ
CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX	May. 10	PR
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024	Apr. 26	AQ
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX	Apr. 25	BU
CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE	Apr. 25	AQ
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million	Apr. 24	AQ
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline	Apr. 24	AQ
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Apr. 22	AQ
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice	Apr. 22	AQ
Cidara Therapeutics Announces Reverse Stock Split	Apr. 22	AQ
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024	Apr. 05	AQ
CIDARA THERAPEUTICS TO PRESENT PRECLINCAL DATA ON MULTIPLE NOVEL DRUG-FC CONJUGATE CANDIDATES AT AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2024	Mar. 07	AQ
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024	Mar. 06	AQ
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO	Feb. 12	AQ
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults	Jan. 29	AQ
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults	Dec. 22	AQ
Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress	Dec. 07	AQ
Melinta Therapeutics and Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE trial and Phase 2 STRIVE Trial of REZZAYO for the Treatment of Candidemia	Dec. 06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cidara Therapeutics, Inc.

Equities

CDTX

US1717572069

Press Releases

Filters